Author’s Response

In the comment by Dr Tripepi, “Alternative Explanation of the Results,” I respectfully disagree with assertions that we misinterpreted our findings. Our specific aim was to determine the different effects of palivizumab on hospitalizations with an RSV diagnosis and hospitalizations without an RSV diagnosis. We clearly showed differences and a dose–response effect.1 It appears Dr Tripepi would like an analysis of pooled hospitalization rates (hospitalization with RSV diagnosis plus hospitalization for bronchiolitis without an RSV diagnosis) for infants born at 29 to 32 weeks’ gestation to determine whether there is a net benefit or harm. When we sum RSV and non-RSV hospitalizations … E-mail: hjfarber{at}texaschildrens.org